Skip to main content
AVACTA GROUP PLC logo

AVACTA GROUP PLC — Investor Relations & Filings

Ticker · AVCT ISIN · GB00BYYW9G87 LEI · 2138009U3EG31OPMGH36 IL Manufacturing
Open in API
Filings indexed 708 across all filing types
Latest filing 2024-02-29 Regulatory Filings
Country GB United Kingdom
Listing IL AVCT

About AVACTA GROUP PLC

https://avacta.com/

Avacta Group PLC is a clinical-stage biotechnology company developing targeted oncology drugs. The company's core technology is the proprietary pre|CISION® platform, a drug delivery system designed to improve the safety and efficacy of potent cancer therapies. The platform works by linking a peptide to a cancer drug, rendering it inactive in the bloodstream. The drug is precisely activated only within the tumor microenvironment by the Fibroblast Activation Protein (FAP) enzyme, which is abundant in many solid tumors. This approach aims to concentrate the active therapy at the tumor site, thereby reducing systemic toxicity and improving the therapeutic window for patients. The company is advancing a pipeline of peptide drug conjugates (PDCs) based on this platform.

Recent filings

Filing Released Lang Actions
Result of Placing
Regulatory Filings Classification · 98% confidence The document is an official announcement from Avacta Group PLC, identified by the RNS Number and the date stamp (29 February 2024). The core content details the successful completion of a 'Placing' (a fundraising activity) where new shares were issued to investors, increasing the size of the fundraising from £20 million to £25.7 million. It also mentions concurrent subscriptions by Directors and outlines the total voting rights and admission timelines for the new shares. This activity—raising capital through the issuance of shares—directly corresponds to the definition of a Capital/Financing Update. Although it involves share issuance (SHA) and director dealings (DIRS), the primary purpose and focus of the entire announcement is the successful completion of the capital raise (Placing). Therefore, 'Capital/Financing Update' (CAP) is the most appropriate classification.
2024-02-29 English
Proposed REX Retail Offer
Capital/Financing Update Classification · 98% confidence The document is an official announcement from Avacta Group PLC, identified by the RNS Number (8448E) and the date (28 February 2024). The content explicitly details a 'Proposed REX Retail Offer' and other fundraising activities (Firm Placing, Conditional Placing, Direct Subscription) involving the issuance of new Ordinary Shares. This clearly falls under the category of company fundraising and capital structure changes. The most appropriate classification is 'Capital/Financing Update' (CAP). Although it is distributed via RNS, the core subject matter is the capital raise, not just a general regulatory update.
2024-02-28 English
Proposed Fundraise to progress Therapeutics
Share Issue/Capital Change Classification · 99% confidence The document is an official announcement dated February 28, 2024, from Avacta Group PLC, detailing a 'Proposed Fundraise' comprising a Firm Placing, Direct Subscription, and a Conditional Placing/REX Offer. The core subject is raising capital ('up to £13.8 million' plus potential additional proceeds) to fund clinical pipeline progression (AVA6000, AVA3996). This clearly falls under the category of financing activities and capital structure changes. Therefore, the appropriate classification is Capital/Financing Update (CAP). Although it is an RNS announcement, the content is substantive and specific to a capital raise, making CAP more precise than the general RNS fallback.
2024-02-28 English
Share Incentive Plan/Issue of Equity
Remuneration Information Classification · 99% confidence The document is identified by the header 'RNS Number : 3582D' and contains information about the issuance of new ordinary shares as part of an HMRC Approved Share Incentive Plan (SIP). This action directly relates to a change in the company's share capital structure and the issuance of new shares to employees. This aligns precisely with the definition of 'Share Issue/Capital Change' (Code: SHA). Although it is distributed via RNS, the core subject matter is a capital change, making SHA the most specific classification over the general 'RNS' fallback.
2024-02-16 English
Issue of Equity and Total Voting Rights
Share Issue/Capital Change Classification · 99% confidence The document is identified by the header 'RNS Number : 4688A' and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content details the 'Issue of Equity and Total Voting Rights' resulting from a convertible bond settlement, which is a material corporate action announcement. This type of mandatory, timely disclosure to the market, especially one originating from the RNS system, fits best under the general 'Regulatory Filings' category, as it is not a full financial report (10-K, IR), a specific management change (MANG), or a dividend notice (DIV). While it relates to share capital changes (SHA), the primary nature here is a regulatory announcement via the RNS system.
2024-01-22 English
Appointment of Christina Coughlin
Board/Management Information Classification · 98% confidence The document begins with 'RNS Number' and is dated '19 January 2024'. It announces the 'Appointment of Christina Coughlin, M.D., Ph.D. as Head of Research and Development' and the stepping down of another executive. This content clearly relates to changes in senior management/board composition. This aligns perfectly with the definition for Board/Management Information (MANG). Although it is distributed via RNS, the core subject matter is management change, making MANG the most specific classification. The document length is substantial (8055 chars), so it is not a simple RPA.
2024-01-19 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.